KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

PRIMPERAN 2 ML INJECTION

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

2 ML

 

GENERIC NAME:

METOCLOPRAMIDE

 

MANUFACTURER:

SANOFI SYNTHELABO

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B

 

INDICATIONS:

Gastroesophageal Reflux Disease

Gastroparesis, diabetic

Intubation, intestinal

Nausea, postoperative

Nausea, secondary to cancer chemotherapy

Vomiting, postoperative

Vomiting, secondary to cancer chemotherapy

 

SIDE EFFECTS:

Agranulocytosis

cardiovascular effects, specifically hypotension

hypertension

tachycardia

extrapyramidal effects, dystonic

extrapyramidal effects, parkinsonian

tardive dyskinesia

Agitation

panic-like sensation

restless legs syndrome

Diarrhea

drowsiness

restlessness

unusual tiredness or weakness

Breast tenderness and swelling

changes in menstruation

constipation

dizziness

headache

insomnia

mental depression

prolactin stimulation

nausea

skin rash

unusual dryness of mouth

unusual irritability

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

Asthma

Depression, mental

Hypertension

Parkinson's disease

>> Renal failure, severe, chronic

 

ADULT DOSE:

Gastrointestinal emptying (delayed) adjunct or Peristaltic stimulant- Intravenous, 10 mg as a single dose. [Treatment of hiccups] - Intramuscular, 10 mg initially, followed by oral metoclopramide at a dose of 10 to 20 mg four times a day for seven days. Antiemetic: For prevention of cancer chemotherapy-induced emesis- Intravenous infusion, 2 mg per kg of body weight, administered thirty minutes before cisplatin or other highly emetogenic chemotherapeutic agent; may be repeated as needed every two or three hours. Note: For prevention of emesis induced by chemotherapeutic agents with low emetic potential-Intravenous infusion, 1 mg per kg of body weight. Continuous intravenous infusion, 3 mg per kg of body weight before chemotherapy, followed by 0.5 mg per kg of body weight per hour for eight hours. Antiemetic: For prevention of postoperative emesis- Intramuscular, 10 to 20 mg near the end of surgery.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Antiemetic-For prevention of cancer chemotherapy-induced emesis or Gastrointestinal emptying (delayed) adjunct or Peristaltic stimulant- Intravenous, 1 mg per kg of body weight as a single dose. May be repeated one time after sixty minutes. Note: To reduce the chance of increased adverse reactions, dosages should not exceed 2 mg per kg of body weight. Some clinicians recommend concurrent therapy with diphenhydramine at an intravenous dose of 1 mg per kg of body weight 15 minutes prior to metoclopramide infusion to limit side effects that may occur with doses of less than 2 mg per kg of body weight. 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT